Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial
Posted inDiabetes & Endocrinology Specialties

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial

This review synthesizes evidence from a multicentre, phase 3 trial on ecnoglutide, demonstrating significant and sustained weight loss in overweight/obese adults without diabetes, with a favorable safety profile, supporting its clinical use in weight management.
Improving Sleep Quality through Cognitive Behavioural Therapy Alters Food Preferences in Adults with Overweight and Obesity
Posted inDiabetes & Endocrinology Gastroenterology Neurology news Specialties

Improving Sleep Quality through Cognitive Behavioural Therapy Alters Food Preferences in Adults with Overweight and Obesity

Cognitive behavioural therapy for insomnia enhances self-reported sleep quality and duration, reduces cravings for sweet and savoury foods, and shifts implicit food preferences in adults with overweight or obesity, though dietary intake changes remain uncertain.
Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers
Posted inCardiology Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.